The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis

The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis

Abstract The efficacy of neoadjuvant therapy varies significantly with hormone receptor (HR) status for patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC). Despite extensive research on HER2 + BC, the optimal neoadjuvant strategy for HR+/HER2 + BC remains incon...

Full description

Saved in:
Bibliographic Details
Main Authors: Shiwei Liu, Miao Yu, Exian Mou, Meihua Wang, Shuanghua Liu, Li Xia, Hui Li, Hao Tang, Yajing Feng, Xin Yu, Kun Mi, Hao Wang
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Breast cancer
HER2 positive
HR positive
Neoadjuvant therapy
Targeted therapy
Network meta-analysis
Online Access:https://doi.org/10.1038/s41598-024-84039-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-84039-2

Similar Items